WO2004110973A1 - Complexes de platine antitumoraux a radicaux camphriques comme ligands - Google Patents
Complexes de platine antitumoraux a radicaux camphriques comme ligands Download PDFInfo
- Publication number
- WO2004110973A1 WO2004110973A1 PCT/CN2004/000585 CN2004000585W WO2004110973A1 WO 2004110973 A1 WO2004110973 A1 WO 2004110973A1 CN 2004000585 W CN2004000585 W CN 2004000585W WO 2004110973 A1 WO2004110973 A1 WO 2004110973A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- platinum
- formula
- camphorate
- complexes
- camphoric
- Prior art date
Links
- HRGDZIGMBDGFTC-UHFFFAOYSA-N platinum(2+) Chemical class [Pt+2] HRGDZIGMBDGFTC-UHFFFAOYSA-N 0.000 title claims abstract description 19
- 230000000259 anti-tumor effect Effects 0.000 title claims description 6
- 239000003446 ligand Substances 0.000 title abstract description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 30
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims abstract description 28
- 229910052697 platinum Inorganic materials 0.000 claims abstract description 13
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract description 6
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 6
- 230000003287 optical effect Effects 0.000 claims abstract description 6
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims abstract description 5
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 4
- 230000005764 inhibitory process Effects 0.000 claims abstract description 4
- 238000002360 preparation method Methods 0.000 claims abstract description 4
- YMHQVDAATAEZLO-UHFFFAOYSA-N cyclohexane-1,1-diamine Chemical compound NC1(N)CCCCC1 YMHQVDAATAEZLO-UHFFFAOYSA-N 0.000 claims abstract description 3
- 230000001093 anti-cancer Effects 0.000 claims abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 28
- -1 platinum amine Chemical class 0.000 claims description 18
- 229910052757 nitrogen Inorganic materials 0.000 claims description 16
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 8
- 208000032839 leukemia Diseases 0.000 claims description 5
- 201000007270 liver cancer Diseases 0.000 claims description 5
- 208000014018 liver neoplasm Diseases 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- XKUTVNLXHINPAP-UHFFFAOYSA-N azane platinum Chemical compound N.[Pt] XKUTVNLXHINPAP-UHFFFAOYSA-N 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 150000004985 diamines Chemical class 0.000 claims description 4
- 150000001450 anions Chemical class 0.000 claims description 3
- 150000002500 ions Chemical class 0.000 claims description 3
- SSJXIUAHEKJCMH-PHDIDXHHSA-N (1r,2r)-cyclohexane-1,2-diamine Chemical group N[C@@H]1CCCC[C@H]1N SSJXIUAHEKJCMH-PHDIDXHHSA-N 0.000 claims description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 claims description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 2
- 241000723346 Cinnamomum camphora Species 0.000 claims description 2
- 229910052783 alkali metal Inorganic materials 0.000 claims description 2
- 125000003277 amino group Chemical group 0.000 claims description 2
- 229910021529 ammonia Inorganic materials 0.000 claims description 2
- QSKKXNSTGHZSQB-UHFFFAOYSA-N azane;platinum(2+) Chemical compound N.[Pt+2] QSKKXNSTGHZSQB-UHFFFAOYSA-N 0.000 claims description 2
- 229960000846 camphor Drugs 0.000 claims description 2
- 229930008380 camphor Natural products 0.000 claims description 2
- 150000001768 cations Chemical class 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000003058 platinum compounds Chemical class 0.000 claims description 2
- 229910052709 silver Inorganic materials 0.000 claims description 2
- 239000004332 silver Substances 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- YIAQFQFVWJGXQE-UHFFFAOYSA-N [Ag].CC1(C)C2CCC1(C)C(=O)C2 Chemical compound [Ag].CC1(C)C2CCC1(C)C(=O)C2 YIAQFQFVWJGXQE-UHFFFAOYSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 238000000338 in vitro Methods 0.000 abstract description 8
- 125000002091 cationic group Chemical group 0.000 abstract description 2
- 230000000694 effects Effects 0.000 abstract description 2
- 150000003057 platinum Chemical class 0.000 abstract description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 150000001412 amines Chemical class 0.000 abstract 1
- 125000000129 anionic group Chemical group 0.000 abstract 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 25
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 12
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 8
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 229960004316 cisplatin Drugs 0.000 description 7
- 239000005909 Kieselgur Substances 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- DVQHYTBCTGYNNN-UHFFFAOYSA-N azane;cyclobutane-1,1-dicarboxylic acid;platinum Chemical compound N.N.[Pt].OC(=O)C1(C(O)=O)CCC1 DVQHYTBCTGYNNN-UHFFFAOYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 229960004562 carboplatin Drugs 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 229910001961 silver nitrate Inorganic materials 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- LSPHULWDVZXLIL-LDWIPMOCSA-N (?)-Camphoric acid Chemical compound CC1(C)[C@@H](C(O)=O)CC[C@@]1(C)C(O)=O LSPHULWDVZXLIL-LDWIPMOCSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- UMWYYMCOBYVEPY-UHFFFAOYSA-N azanide;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2] UMWYYMCOBYVEPY-UHFFFAOYSA-N 0.000 description 3
- 230000017095 negative regulation of cell growth Effects 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- SGLJYTWMWIAGEU-KGZKBUQUSA-N (1r,2r)-cyclohexane-1,2-diamine;platinum(2+) Chemical compound [Pt+2].N[C@@H]1CCCC[C@H]1N SGLJYTWMWIAGEU-KGZKBUQUSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- IELGANLONSBBOO-ZJLYAJKPSA-N [(4R,5R)-5-(aminomethyl)-2-propan-2-yl-1,3-dioxolan-4-yl]methanamine platinum(2+) Chemical compound [Pt+2].CC(C)C1O[C@H](CN)[C@@H](CN)O1 IELGANLONSBBOO-ZJLYAJKPSA-N 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- UEBVTWPOGCMDPV-UHFFFAOYSA-N platinum;n-propan-2-ylpropan-2-amine Chemical compound [Pt].CC(C)NC(C)C UEBVTWPOGCMDPV-UHFFFAOYSA-N 0.000 description 2
- IBZKBSXREAQDTO-UHFFFAOYSA-N 2-methoxy-n-(2-methoxyethyl)ethanamine Chemical compound COCCNCCOC IBZKBSXREAQDTO-UHFFFAOYSA-N 0.000 description 1
- BKGOEKOJWMSNRX-UHFFFAOYSA-L C(C1(C)C(C)(C)C(C(=O)[O-])CC1)(=O)[O-].[Ag+2] Chemical compound C(C1(C)C(C)(C)C(C(=O)[O-])CC1)(=O)[O-].[Ag+2] BKGOEKOJWMSNRX-UHFFFAOYSA-L 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- UUOFRXDFODYHPC-RNFRBKRXSA-N [(4r,5r)-5-(aminomethyl)-2-propan-2-yl-1,3-dioxolan-4-yl]methanamine Chemical compound CC(C)C1O[C@H](CN)[C@@H](CN)O1 UUOFRXDFODYHPC-RNFRBKRXSA-N 0.000 description 1
- OFIQFCVXZDCKTN-ZJLYAJKPSA-N [(4r,5r)-5-(aminomethyl)-2-propan-2-yl-1,3-dioxolan-4-yl]methanamine;platinum Chemical compound [Pt].CC(C)C1O[C@H](CN)[C@@H](CN)O1 OFIQFCVXZDCKTN-ZJLYAJKPSA-N 0.000 description 1
- IELGANLONSBBOO-LEUCUCNGSA-N [(4s,5s)-5-(aminomethyl)-2-propan-2-yl-1,3-dioxolan-4-yl]methanamine;platinum(2+) Chemical compound [Pt+2].CC(C)C1O[C@@H](CN)[C@H](CN)O1 IELGANLONSBBOO-LEUCUCNGSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- PNCHTLQBARZRSO-UHFFFAOYSA-L azane;platinum(2+);diiodide Chemical compound N.N.[I-].[I-].[Pt+2] PNCHTLQBARZRSO-UHFFFAOYSA-L 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 125000001142 dicarboxylic acid group Chemical group 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000005918 in vitro anti-tumor Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- MILNMWLYQBNWPH-UHFFFAOYSA-N platinum(2+);propan-2-amine Chemical compound [Pt+2].CC(C)N.CC(C)N MILNMWLYQBNWPH-UHFFFAOYSA-N 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D317/28—Radicals substituted by nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/65—Metal complexes of amines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C61/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C61/06—Saturated compounds having a carboxyl group bound to a five-membered ring
Definitions
- the present invention relates to a novel platinum (II) complex having effective antitumor activity, a preparation method thereof, and an in vitro antitumor property of a typical compound in the platinum ( ⁇ ) complex.
- the object of the present invention is to provide novel cisplatin ( ⁇ ) complexes containing dicarboxylic acid radicals. These complexes have low toxicity, better water solubility, and effective antitumor activity, and are used for treating human tumors.
- the invention discloses a new type of platinum (II) coordination compound, which is characterized in that a new type of platinum (II) coordination compound formed by reacting camphorate as a complex anion with a platinum amine complex cation is used.
- the composition of this type of compound is represented by the following formulas (1), (2), (3) ⁇
- camphor acid in formula (1), formula (2) and formula (3) can be a racemate, D-type optical isomer [(1R, 3SH +)-camphorate] or L-type optical isomer [(1S, 3R)-(-)-camphorate].
- the R groups in the formula (1) are the same, and they are a hydrogen atom, a fluorenyl group, or a CMoxepinyl group; the cyclohexanediamine in the formula (2) is 1,2-transcyclohexanediamine.
- the absolute configuration of the sex carbon atom (marked with *) is either R configuration or S configuration; 4,5-bis (aminomethyl) -2-alkyl-1,3-di in formula (3)
- the oxolane ring is the same as or different from the hydrogen atom or -5 alkyl group, respectively, or can be combined with a carbon atom to form a cycloalkyl group.
- the absolute configuration of both chiral carbon atoms (labeled with *) It is in the R or S configuration.
- the platinum complex of the present invention includes all stereoisomers and mixtures thereof represented by the above chemical formula.
- Another object of the present invention is to provide a method for preparing a platinum ( ⁇ ) complex represented by formula (1), formula (2) and formula (3).
- these divalent platinum complexes they are firstly obtained by the action of potassium tetrachloroplatinate and related diamine (ammonia) ligands to obtain a platinum compound containing a dihalide ion diamine coordination, from the formula (4a) And (4b).
- method A using silver ions to remove the halogen ions of dihalodiamine (ammonia) platinum ( ⁇ ), and the obtained intermediate interacts with the monobasic alkali metal cation or ammonium ion camphorate Cis- (camphorate) ⁇ diamine (ammonia) platinum ( ⁇ ) compound; or method B: cis- (camphorate) is obtained by using silver camphorate and dihalodiamine (ammonia) platinum (II) ) • Diamine (ammonia) platinum ( ⁇ ) compounds.
- Hal in the formulae (4a) and 4 (b) represents Cr, and ⁇ ions, wherein the R groups in the formula (4a) are the same, and they are a hydrogen atom or a ⁇ -5 alkyl group or an oxaalkyl group, respectively, and the formula (4b) Attached to an amine nitrogen atom
- the circular arc indicates that the two amine groups are connected by an alkyl group.
- Another object of the present invention is to disclose the in vitro inhibitory effect of the typical compounds in the above platinum (II) complex on human leukemia cells, ovarian cancer cells, liver cancer cells and lung cancer cells.
- Representative compounds of the invention include:
- Cis- (D-camphorate) ⁇ diisopropylamine platinum ( ⁇ ) (slightly: GS-2b);
- GS-9a Cis- (DL-camphorate) ⁇ bis (2-methoxyethylamine) platinum ( ⁇ ) (abbreviated: GS-9a); cis- (D-camphorate) ⁇ bis (2-methoxyethyl) Amine) platinum ( ⁇ ) (abbreviated: GS-9b).
- the invention is further illustrated by the following examples, but these descriptions do not limit the invention.
- Example 1 Synthesis of cis- (DL-camphorate) ⁇ diaminoplatinum (II)
- Cis-diiodo-diammine platinum (II) (0.97 g, 2 mmol) and silver nitrate (0.68 g, 4 mmol) were mixed with water (50 ml), and reacted at 60 ° C in the absence of light and nitrogen for 24 hours.
- Diatomaceous earth assisted filtration and an aqueous solution of DL-camphoric acid (0.40 g, 4 mmol) and sodium hydroxide (0.16 g, 4 mmol) was added to the filtrate, and reacted at 60 ° C in the absence of light and nitrogen for 16 hours.
- the solution was concentrated and a large amount of white solid precipitated. It was filtered, washed repeatedly with water, ethanol, and ether, and dried under vacuum at 60 ° C to obtain 0.41 g (48%) of the product.
- ⁇ -NMRCDaO / TMS ⁇ 0.47-0.67 (m, 3H), 0.91-1.08 (m, 6H), 1.24-1.31 (s, 1H), 1.60 (s, 1H), 1.74-1.75 (s, 1H) , 2.08 (m, 1H), 2.55-2.56 (s, 1H)
- Cis-diiodide [(4R, 5R) -4,5-bis (aminomethyl) -2-isopropyl-1,3-dioxolane] platinum (II) (1.25 g, 2 mmol ), Silver nitrate (0.68 g, 4 mmol) mixed with water (50 ml), reacted under nitrogen at 60 ° C for 24 hours, filtered with diatomaceous earth, and D- camphoric acid (0.40 g, 4 Mmol) was reacted with an aqueous solution of sodium hydroxide (0.16 g, 4 mmol) at 60 ° C in the absence of light and nitrogen for 16 hours, and the solution was concentrated to precipitate a large amount of white solid.
- Cis-diiodobis (2-methoxyethylamine) platinum ( ⁇ ) (1.20 g, 2 mmol) and silver nitrate (0.68 g, 4 mmol) were mixed with water (50 ml), 60 ° Reaction under nitrogen at 24 ° C for 24 hours, filtered with diatomaceous earth, and an aqueous solution of DL-camphoric acid (0.40 g, 4 mmol) and sodium hydroxide (0.16 g, 4 mmol) was added to the filtrate at 60 ° C. After reacting for 16 hours in the absence of light and nitrogen, the solution was concentrated to precipitate a large amount of white solid. It was filtered, washed repeatedly with water, ethanol, and ether, and dried under vacuum at 60 ° C to obtain 0.54 g (50%) of the product.
- Cell lines HL-60 human leukemia cells, 3A0 human ovarian cancer cells, BEL-7402 human liver cancer cells, A549 human lung cancer cells.
- the drug concentration was divided into three groups: 100, 10, 1, 0.1, 0.01 (g / ml).
- the inhibition rate was calculated based on the efficacy evaluation. Observe the inhibitory effect of the drug on the growth of tumor cells at different concentrations, with cisplatin and carboplatin as reference.
- Figure 1 shows the compound GI 5 on HL-60 cells.
- Figure 2 shows the compound GI 5 on 3A0 cells.
- Figure 3 shows the compound GI 5 on BEL-7402 cells.
- Figure 4 shows the GI 5Q value of the compound on A549 cells.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
樟脑酸根为配体的抗肿瘤铂 (Π)配合物
一. 技术领域
本发明涉及具有有效抗肿瘤活性的新型铂 (II)配合物、 其制备方法 和所述铂 (Π)配合物中典型化合物的体外抗肿瘤性质。 二. 背景技术
在顺铂类抗癌药物研究中, 作为离去基团的阴离子的特性对药物 的活性影响很大。 如果采用不稳定的离去基团, 化合物的毒性将增大; 如果使用惰性的离去基团, 化合物则通常无活性。 自含有环丁二酸根的 卡铂研制成功后, 二元羧酸在抗肿瘤铂 (II)配合物药物的研发中一直扮 演重要的角色。 如乙二酸、 丙二酸和去甲斑蝥酸都已得到实际应用。 因 此设计与合成含有二元羧酸根的具有低毒和水溶性好的顺铂类化合物 来改进抗肿瘤制剂是一条重要的途径。 三. 发明内容
本发明的目的是在于提供新型的含有二元羧酸根的顺铂 (Π)类配合 物, 这些配合物具有低毒、 较好水溶性、 有效的抗肿瘤活性, 用于治疗 人类肿瘤。 本发明公开了一类新型铂 (II)配位化合物, 其特征在于应用 樟脑酸根为配阴离子与铂胺配阳离子反应形成的新型铂 (II)配位化合 物。 该类化合物的组成由下面 (1)、 (2)、 (3)式表示-
其中式 (1)、 式 (2)和式 (3)中的樟脑酸根可以是其外消旋体、 D型旋光异 构体 [(1R,3SH+)-樟脑酸根]或 L型旋光异构体 [(lS,3R)-(-)-樟脑酸根]。 式 ( 1)中的 R基团相同, 分别为氢原子、 垸基或 CM氧杂垸基; 式 (2) 中的环己二胺为 1 ,2-反式环己二胺,两个手性碳原子 (标有 *号)的绝对构 型都为 R构型或 S构型;式 (3)中的 4,5-二 (氨甲基) -2-烷基 -1 ,3-二氧戊环 所示 和 相同或不相同, 分别为氢原子或 -5烷基, 或可与一碳 原子联结形成环烷基, 两个手性碳原子 (标有 *号)的绝对构型都为 R构 型或 S构型。本发明的铂配合物包括上述化学式所示的所有立体异构体 及其混合物。
本发明的另一个目的是提供制备式 (1)、 式 (2)和式 (3)所示的铂 (Π) 配合物的方法。在这些二价铂配合物的合成中, 它们首先是由四氯合铂 酸钾与相关的二胺(氨)配体作用得到含二卤素离子二胺配位的铂化合 物, 由式 (4a)和(4b)代表。 然后在避光通氮气条件下, 通过方法 A: 使 用银离子除去二卤二胺 (氨)合铂 (Π)的卤素离子,所得中间体与一价碱金 属阳离子或铵离子的樟脑酸盐作用得到顺- (樟脑酸根) ·二胺 (氨)合铂 (Π) 化合物; 或通过方法 B : 使用樟脑酸银盐与二卤二胺 (氨)合铂 (II)作用得 到顺- (樟脑酸根) ·二胺 (氨)合铂 (Π)化合物。
式 (4a)和 4(b)中的 Hal代表 Cr、 和 Γ离子, 其中式 (4a)的 R基团相 同, 分别为氢原子或^— 5烷基或 氧杂烷基, 式 (4b)连在胺氮原子上
的圆弧表示两个胺基由烷基相连。
本发明还有一个目的是公开上述铂 (II)配合物中典型化合物对人体 白血病细胞、 卵巢癌细胞、 肝癌细胞和肺癌细胞的体外抑制作用。
本发明有代表性的化合物包括:
顺- (DL-樟脑酸根) ·二氨合铂 (II) (略为: GS-la);
顺- (D-樟脑酸根) ·二氨合铂 (II) (略为: GS-lb) ;
顺 -(DL-樟脑酸根) ·二异丙胺合铂 (Π) (略为: GS-2a);
顺 -(D-樟脑酸根) ·二异丙胺合铂 (Π) (略为: GS-2b);
顺- (DL-樟脑酸根) ·(1,2-反式环己二胺)合铂 (II) (略为: GS-3a) ;
顺- (D-樟脑酸根) ·(1,2-反式环己二胺)合铂 (II) (略为: GS-3b);
顺- (DL-樟脑酸根) · [(1R,2R)-1,2-反式环己二胺]合铂(II) (略 为: GS-4a);
顺- (D-樟脑酸根) · [(1R,2R)-1,2-反式环己二胺]合铂(II) (略 为: GS-4b);
顺- (DL-樟脑酸根) · [(1S,2S)- 1,2-反式环己二胺]合铂(II) (略 为: GS-5a);
顺- (D-樟脑酸根) · [(1&25)- 1,2-反式环己二胺]合铂(II) (略 为: GS-5b);
顺 -(DL-樟脑酸根) *[4,5-二 (氨甲基) -2-异丙基 -1,3-二氧戊环]合铂 (II) (略为: GS-6a);
顺- (D-樟脑酸根) · [4,5-二 (氨甲基) -2-异丙基 -1,3-二氧戊环]合铂 (II) (略为: GS-6b);
顺- (DL-樟脑酸根) · [(4R,5R)-4,5-二 (氨甲基) -2-异丙基 -1,3-二氧戊 环]合铂 (II) (略为: GS-7a);
顺- (D-樟脑酸根) '[(4R,5R)-4,5-二 (氨甲基) -2-异丙基 - 1,3-二氧戊环] 合铂 (II) (略为: GS-7b) ;
顺- (DL-樟脑酸根) *[(4&55 4,5-二 (氨甲基) -2-异丙基 -1,3-二氧戊环]
合铂 (II) (略为: GS-8a:)。
顺 -(D-樟脑酸根) · [(4&55)-4,5-二 (氨甲基) -2-异丙基 -1,3-二氧戊环] 合铂 (Π) (略为: GS-8b);
顺 -(DL-樟脑酸根) ·二 (2-甲氧基乙基胺)合铂(Π ) (略为: GS-9a); 顺 -(D-樟脑酸根) ·二 (2-甲氧基乙基胺)合铂(Π ) (略为: GS-9b)。 本发明由下述实施例得到进一步的阐述,但这些说明并不是限制本 发明。
按本发明所制备的化合物的结构已被不同的分析方法诸如元素分 析、 红外光谱、质子核磁共振光谱和阳离子电喷雾质谱所证实。 以下为 本发明方法制备一些代表性化合物的实施例。 实施例 1 : 合成顺 -(DL-樟脑酸根) ·二氨合铂 (II)
顺-二碘 ·二氨合铂 (II) (0.97 克, 2毫摩尔)、 硝酸银 (0.68 克, 4 毫摩尔)混合加入水 (50毫升), 60°C下避光通氮气反应 24小时, 硅藻土 辅助过滤, 滤液中加入 DL-樟脑酸 (0.40克, 4毫摩尔)与氢氧化钠 (0.16 克, 4毫摩尔)的水溶液, 60°C下避光通氮气反应 16小时, 将溶液浓缩, 析出大量白色固体。 过滤, 用水、 乙醇、 乙醚反复洗涤, 60°C下真空干 燥, 得产物 0.41g(48%)。
IR(KBr): 3424vs (br), 3266vs (br), 2967m, 288 lw, 1594vs, 1544vs, 1460m: 1384vs, 1355vs
^-NMRCDaO/TMS): δ 0.47-0.67 (m, 3H), 0.91-1.08 (m, 6H), 1.24-1.31 (s, 1H), 1.60 (s, 1H), 1.74-1.75 (s, 1H), 2.08 (m, 1H), 2.55-2.56 (s, 1H)
ESI-MS: [M+甲醇 +H]+ = 460 (30%), [M+H]+ = 428 (6%)
顺 -二碘 ·二 (异丙胺)合铂(II ) (1.13克, 2毫摩尔)、 硝酸银(0.68 克, 4毫摩尔)混合加入水 (50毫升), 60°C下避光通氮气反应 24小时, 硅藻土辅助过滤, 滤液中加入 DL-樟脑酸 (0.40克, 4毫摩尔)与氢氧化 钠 (0.16克, 4毫摩尔)的水溶液, 60°C下避光通氮气反应 16小时, 将 溶液浓缩, 析出大量白色固体。 过滤, 用水、 乙醇、 乙醚反复洗涤, 60 °C下真空干燥, 得产物 0.39g(38%)。
IR(KBr): 3430 s (br),3217 s (sh, br), 2971 vs, 2880 w, 1595 vs (br), 1462 m, 1383 vs, 1351 vs, 1164 w, 1118 w
1H-NMR(DMSO-d6/TMS): δ 0.70-0.85 (m, 3H), 0.97-1.26 (m, 18H), 1.44-2.36 (br, 4H), 2.64-2.70 (br, 1H, CH), 2.96-3.18 (m, 2H), 5.85-5.99 (br, NH2)
ESI-MS: [M+甲醇 +H]+ = 544 ( 100%), [M+H]+ = 512 (44%) 实施例 3 : 合成顺 -(D-樟脑酸根) · [(1R,2R)-1,2 反式环己二胺]合铂(II ) 顺 -二氯 *[(1 2 -1,2-反式环己二胺]合铂(II ) (0.76克, 2毫摩尔)、 硝酸银(0.68克, 4毫摩尔)混合加入水 (50毫升), 60°C下避光通氮气反 应 24小时,硅藻土辅助过滤,滤液中加入 D-樟脑酸 (0.40克, 4毫摩尔) 与氢氧化钠 (0.16克, 4毫摩尔)的水溶液, 60°C下避光通氮气反应 16 小时, 将溶液浓缩, 析出大量白色固体。 过滤, 用水、 乙醇、 乙醚反复 洗涤, 60°C下真空干燥, 得产物 0.65g(64%)。
IR(KBr): 3424 vs (br), 3226 s (sh, br), 2939 s, 2872 w, 1598 vs (br), 1457 m, 1381 vs, 1350 s, 1169 w, 1126 w, 1063w
1H-NMR(DMSO-d6/TMS): δ 0.84-0.91 (m, 3H), 1.09-1.20 (m, 6H), 1.28 (m, 4H ), 1.48 (m, 2H), 1.57- 1.62 (m, 3H), 2.08-2.22 (m, 3H), 2.41-2.57 (m, 3H), 5.87-6.44 (br, NH2)
ESI-MS: [M+甲醇 +H]+ = 540 (100%), [M+H]+ = 508 (40%)
实施例 4: 合成顺 -(D-樟脑酸根) · [(4R,5R)-4,5-二 (氨甲基) -2-异丙基 -1, 3-二氧戊环]令铂(II )
顺 -二碘 · [(4R, 5R)-4,5-二 (氨甲基) -2-异丙基 - 1,3-二氧戊环]合铂(II ) (1.25克, 2毫摩尔)、 硝酸银(0.68克, 4毫摩尔)混合加入水 (50毫升), 60°C下避光通氮气反应 24小时, 硅藻土辅助过滤, 滤液中加入 D-樟脑 酸 (0.40克, 4毫摩尔)与氢氧化钠 (0.16克, 4毫摩尔)的水溶液, 60°C 下避光通氮气反应 16小时, 将溶液浓縮, 析出大量白色固体。 过滤, 用水、 乙醇、 乙醚反复洗涤, 60°C下真空干燥, 得产物 0.55g(49%)。 IR(KBr): 3424 s (br), 3220 s (sh, br), 2966 m, 2881 w, 1620- 1559 s (br),
1460 m, 1383 vs, 1357 s, 1125 m, 1093s
^-NMRCDMSO-dVlMS): δ 0.77- 1.14 (m, 15H) , 1.58-2.03 (m,3H), 2.45-2.87 (m,7H), 3.22-3.30 (m,2H), 4.82 (s, 1H), 6.40-7.50 (br, NH2) ESI-MS : [M+甲醇 +H]+ = 600 (34%) 实施例 5 : 合成顺 -(D-樟脑酸根) · [(4S, 5S)-4,5-二 (氨甲基) -2-异丙基 -1, 3-二氧戊环]合铂(II )
顺 -二碘 · [(4S, 5S)-4, 5-二 (氨甲基) -2-异丙基 -1, 3-二氧戊环]合铂 ( II ) (1.25 2毫摩尔)、 硝酸银(0.68克, 4毫摩尔)混合加入水 (50毫 升), 60Ό下避光通氮气反应 24 小时, 硅藻土辅助过滤, 滤液中加入 D-樟脑酸 (0.40克, 4毫摩尔)与氢氧化钠 (0.16克, 4毫摩尔)的水溶液, 60°C下避光通氮气反应 16小时, 将溶液浓缩, 析出大量白色固体。 过 滤, 用水、 乙醇、 乙醚反复洗涤, 60 °C下真空干燥, 得产物 0.42g(37 %)。
IR(KBr): 3427 s (br), 3218 s (sh, br), 2966 m, 2881 w, 1621- 1560 s (br),
1461 m, 1381 vs, 1358 s, 1124 m, 1094 s
1H-NMR(DMSO-d6/TMS): δ 0.72- 1.14 (m, 15H), 1.58-1.95 (m,3H), 2.45-2.87 (m,7H), 3.15-3.20 (m,2H), 4.80 (s, lH), 6.50-7.20 (br, NH2)
ESI-MS: [M+甲醇 +H]+=600(100%)
实施例 6: 合成顺 -(DL-樟脑酸根) ·二 (2-甲氧基乙基胺)合铂(II )
顺-二碘 ·二 (2-甲氧基乙基胺)合铂(Π ) (1.20克, 2毫摩尔)、 硝酸 银(0.68克, 4毫摩尔)混合加入水 (50毫升), 60°C下避光通氮气反应 24 小时, 硅藻土辅助过滤, 滤液中加入 DL-樟脑酸 (0.40克, 4毫摩尔)与 氢氧化钠 (0.16克, 4毫摩尔)的水溶液, 60°C下避光通氮气反应 16小 时, 将溶液浓缩, 析出大量白色固体。 过滤, 用水、 乙醇、 乙醚反复洗 涤, 60°C下真空干燥, 得产物 0.54g(50%)。
IR(KBr): 3447 m (br), 3217 m, 3122 m, 2963 m, 2882 m, 2829 w, 1610 vs, 1457 m, 1378 vs, 1346 vs, 1119 s, 1052 m
1H-NMR(DMSO-d6/TMS): δ 0.545-0.712 (m,3H) , 0.93-1.15 (m,6H), 1.22-2.35 (m,4H), 2.49 (m,lH), 2.623 (m,2H), 3.06 (s,3H), 3.42 (s,2H), 5.57-5.91(br,NH2)
ESI-MS: [M+甲醇 +H]+ = 576 (40%)
注: 因 Pt元素丰度较高的同位素有 194Pt、 195Pt和 196Pt, 所以上述化合 物 ESI-MS质谱的准分子离子峰都有三个丰度较高的同位素峰。
四.一些典型化合物对人体白血病细胞、 卵巢癌细胞、 肝癌细胞和肺癌 细胞的体外抑制作用
单体化合物疗效评价: 用药组值 -零时间值
X ioo% = 50所需药物浓度 对照组值 -零时间值
实验方法: 台盼兰排染法, SRB比色法
细胞株: HL-60人白血病细胞, 3A0人卵巢癌细胞, BEL- 7402 人肝癌 细胞, A549 人肺癌细胞。
实验设计: 药物浓度分为 100, 10, 1, 0. 1, 0. 01 ( g/ml)三组。 根 据疗效评价计算抑制率。观察在不同浓度下药物对肿瘤细胞生长的抑制 情况, 顺铂和卡铂作为参照。
有关化合物对四种肿瘤细胞的体外抑制率数据分见表 1、 表 2、 表 3 和表 4。 表 1. 化合物对人白血病细胞 (HL-60)的体外抑制作用率
各浓度 (ng/ml) 下 HL-60 各浓度 ^g/mi) 下 细胞活细胞数(X 104/ml) 细胞生长抑制百分率 (%)
样品名 Time Ctrl
称 Zero 46 100 10 1 0. 1 0. 01 100 10 1 0. 1 0. 01 GI50
6
GS-la 0 8 37 48 ' 50 100 95 23 0 0 2. 57
GS-lb 0 2 34 41 50 100 100 30 12 0 0. 42
GS-2a 0 29 41 48 50 100 43 13 0 0 3. 75
GS-2b 0 26 32 36 56 100 50 35 25 0 2. 61
GS-4a 0 1 22 49、 50 100 100 60 0 0 0. 97
GS-4b 0 5 25 40 49 100 100 53 15 0 0. 34
GS-7a 0 0 22 47 50 100 100 60 0 0 0. 97
GS-7b 0 0 1 24 37 100 100 100 55 23 0. 03 顺铂 0 0 6 28 47 100 100 100 45 0 0. 10 卡铂 0 10 32 40 49 100 90 35 15 0 1. 06
表 2. 化合物对人卵巢细胞 (3A0)的体外抑制作用率
各浓度 ^g/ml) 下 3A0 各浓度 (μβ/πιΐ) 下
细胞活细胞数 (X104/ml) 细胞生长抑制百分率 (%)
样品名称 Time Ctrl
Zero 0.77 100 10 1 0.1 0.01 100 10 1 0.1 0.01 GI50 0.25
GS-la 0. 42 0. 53 0. 66 0. 66 0. 65 67 46 21 21 23 15.3
GS-lb 0. 36 0. 59 0. 64 0. 69 0. 66 79 35 25 15 21 20.8
GS-2a 0. 46 0. 55 0. 63 0. 55 0. 55 60 42 27 42 42 27.7
GS-2b 0. 45 0. 49 0. 47 0. 51 0. 50 62 54 58 50 52 0.1
GS-4a 0. 49 0. 43 0. 43 0. 56 0. 55 54 65 65 40 42 0.25
GS-4b 0. 29 0. 4 0. 45 0. 55 0. 53 92 71 62 42 46 0.25
GS-7a 0. 41 0. 36 0. 53 0. 55 0. 57 69 79 46 42 38 1.28
GS-7b 0. 27 0. 41 0. 49 0. 52 0. 54 96 69 54 48 44 0.22 顺铂 0. 29 0. 28 0. 45 0. 52 0. 53 92 94 62 48 46 0.14 卡铂 0. 3 0. 52 0. 55 0. 55 0. 61 90 48 42 42 31 10.8
表 3. 化合物对人肝癌细胞 (BEL-7402)的体外抑制作用率
各浓度 ( g/ml) 下 BEL-7402 各浓度 (μg/ l) 下
细胞活细胞数 (XlOVml) 细胞生长抑制百分率 (%)
样品名称 Time Ctrl
Zero 1.44 100 10 1 0.1 0.01 100 10 1 ■ 0.1 0.01 0.43
GS-la 0.28 1.07 1.22 1.22 1.16 100 37 22 22 28 11.3
GS-lb 0.36 0.76 1.29 1.33 1.22 100 67 15 11 22 5.13
GS-2a 0.85 1.24 1.2 1.21 1.24 58 20 24 23 20 64.7
GS-2b 0.99 1.03 1.15 1.16 1.18 45 41 29 28 26 >100
GS-4a 0.4 0.85 0.97 1.12 1.21 100 58 47 32 23 1.86
GS-4b 0.43 0.9 1.01 1.14 1.2 100 53 43 29 24 5.02
GS-7a 0.53 0.53 1.21 1.19 1.07 90 90 23 24 37 2.26
GS-7b 0.37 0.5 1.17 1.21 1.14 100 93 27 22 30 1.89 顺铂 0.31 0.30 0.96 1.00 1.13 100 100 48 44 31 0.23 卡铂 0.31 1.23 1.26 1.21 1.23 100 21 18 23 21 13.4
表 4. 化合物对人肺癌细胞 (A549)的体外抑制作用率
各浓度 ( g/ml) TA549 各浓度 ml)下
细胞活细胞数 (XlOVml) 细胞生长抑制百分率 (%)
样品名称 Time Ctrl
Zero 1.95 100 10 1 0.1 0.01 100 10 1 0.1 0.01 GIGO 0.34
GS-la 0. 43 1.28 1. 84 1. 92 1. 74 94 42 7 2 13 78.5
GS-lb 0. 47 1.06 1. 76 1. 86 1. 84 92 55 12 6 7 8.1
GS-2a 1. 25 1.68 1. 79 1. 82 1. 57 43 17 10 8 24 >100
GS-2b ' 1. 11 1.52 1. 71 1. 67 1. 56 52 27 15 17 24 84
GS-4a 0. 57 1.83 1. 54 1. 68 1. 69 86 7 25 17 16 38.7
GS-4b 0. 73 0.96 1. 77 1. 76 1. 56 76 61 11 12 24 6.66
GS-7a 0. 56 1.12 1. 64 1. 7 1. 55 86 52 19 16 25 8.87
GS- 7b 0. 81 0.91 1. 68 1. 82 1. 77 71 65 17 8 11 5.23 顺铂 0. 40 0.32 1. 04 1. 62 1. 58 96 100 57 21 23 0.67 卡铂 0. 39 1.46 1. 56 1. 49 1. 57 97 30 24 29 24 15.7
化合物对相应的肿瘤细胞 GI5D值图见说明书附图。 其中: 图 1为化 合物对 HL— 60细胞 GI5。值, 图 2为化合物对 3A0细胞 GI5。值, 图 3为 化合物对 BEL— 7402细胞 GI5。值, 图 4为化合物对 A549细胞 GI5Q值。
Claims
1、一类具有有效抗癌活性铂 (II)配位化合物, 其特征在于应用樟脑酸根 为配阴离子与铂胺配阳离子反应形成的新型铂 (Π)配位化合物。 该类化 合物的组成由下式表示:
(3)
其中式 (1)、式 (2)和式 (3)中的樟脑酸根可以是其 DL外消旋体、 D型 旋光异构体 [(1R,3SH+)-樟脑酸根]或 L 型旋光异构体 [(lS,3RH- 樟脑 酸根]。 式 (1)中的 R基团相同, 分别为氢原子、 _5烷基或 d.8氧杂烷 基; 式 (2)中的环己二胺为 1,2-反式环己二胺, 两个手性碳原子 (标有 * 号)的绝对构型都为 R构型或 S构型; 式 (3)中的 4,5-二 (氨甲基) -2-烷基 -1,3-二氧戊环所示 和 相同或不相同, 分别为氢原子或 烷基, 或可与一碳原子联结形成环烷基, 两个手性碳原子 (标有 *号)的绝对构 型都为 R构型或 S构型。 本发明的铂配合物包括上述化学式所示的所 有立体异构体及其混合物。
2、 根据权利要求 1所述铂 (Π)配合物的制备方法, 其特征在于将式 (4) 代表的二卤素离子二胺配位的铂化合物在避光通氮气条件下,通过方法 A: 使用银离子除去二卤二胺 (氨)合铂 (Π)的卤素离子, 所得中间体与一 价碱金属阳离子或铵离子的樟脑酸盐作用得到顺- (樟脑酸根),二胺 (氨)
合铂 (II)化合物;或通过方法 B :使用樟脑酸银盐与二卤二胺 (氨)合铂 (II) 作用得到顺- (樟脑酸根) ·二胺 (氨)合铂 (II)化合物。
(4a) (4b)
式 (4a)和 4(b)中的 Hal代表 Cl—、 Br—和 Γ离子, 其中式 (4a)的 R基团按权利 1 所定义, 式 (4b)连在胺氮原子上的圆弧表示两个胺基由垸基相连按权利 1所 定义。
3、 根据权利要求 1所述的铂 (II)配合物和根据权利要求 2所述制备方法获得 的铂 (II)配合物的抗肿瘤活性, 其特征在于这一类铂 (Π)配合物对人体白血病 细胞、 卵巢癌细胞、 肝癌细胞和肺癌细胞的有效抑制作用。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN03131925.4 | 2003-06-19 | ||
CNB031319254A CN1203080C (zh) | 2003-06-19 | 2003-06-19 | 樟脑酸根为配体的抗肿瘤铂(ⅱ)配合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004110973A1 true WO2004110973A1 (fr) | 2004-12-23 |
Family
ID=32001496
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2004/000585 WO2004110973A1 (fr) | 2003-06-19 | 2004-06-02 | Complexes de platine antitumoraux a radicaux camphriques comme ligands |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN1203080C (zh) |
WO (1) | WO2004110973A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110218230B (zh) * | 2018-03-02 | 2022-06-28 | 天津谷堆生物医药科技有限公司 | 维生素c偶联铂配合物、其中间体、其制备方法、药物组合物及用途 |
-
2003
- 2003-06-19 CN CNB031319254A patent/CN1203080C/zh not_active Expired - Fee Related
-
2004
- 2004-06-02 WO PCT/CN2004/000585 patent/WO2004110973A1/zh active Application Filing
Non-Patent Citations (2)
Title |
---|
TANG, WENXIA ET AL.: "Platinum complexes with low toxicity and high activity", ZIRAN ZAZHI, vol. 8, no. 10, 1985, pages 764 - 765 * |
WANG, LONGGUI ET AL: "Effect of camphoramine chloroacetic platinum on biomacromolecules in L1210 leukemia cell", YAOXUE XUEBAO, vol. 22, no. 2, 1987, pages 87 - 92 * |
Also Published As
Publication number | Publication date |
---|---|
CN1203080C (zh) | 2005-05-25 |
CN1478785A (zh) | 2004-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Hidai et al. | Preparation and properties of molybdenum and tungsten dinitrogen complexes. 8. Diazoalkane complexes of molybdenum and tungsten | |
CA1258865A (en) | Platinum complexes | |
EP0306605A1 (en) | Antitumor platinum complexes | |
JP2005220138A (ja) | 1,2−ジアミノシクロヘキサン−白金(ii)−錯体の製造方法 | |
JP3741716B2 (ja) | トリ(白金)錯体 | |
GB2053212A (en) | Cis-platinum(ii)amine lactate complexes | |
US20030032808A1 (en) | Tri-and bidentate amido ligands prepared by palladium0 coupling and metallation threreof to form metal-amido catalysts | |
KR100246722B1 (ko) | 경구용 백금 착화합물 항암제 및 그 제조방법 | |
CN101381380B (zh) | 一类新型的铂(ⅱ)配合物及其抗肿瘤活性 | |
WO2004110973A1 (fr) | Complexes de platine antitumoraux a radicaux camphriques comme ligands | |
US8283473B2 (en) | Platinum complex compound and utilization of the same | |
US8394979B2 (en) | Process for preparing cycloplatinated platinum complexes, platinum complexes prepared by this process and the use thereof | |
Leeaphon et al. | Reactions of the polyhydride complex ReH7 (PPh3) 2 with hydroxypyridine and mercaptopyridine ligands. Formation of hydrido complexes of rhenium (III), rhenium (IV), and rhenium (V) and the characterization of eight-coordinate isomers in the solid state and in solution | |
CN1152036C (zh) | 制备铂(ⅱ)配合物的一种方法 | |
WO2014131281A1 (zh) | 含有芳基位阻基团的二价铂配合物、制备方法及其应用 | |
CN1478786A (zh) | 手性二胺为配体的铂(ⅱ)配合物 | |
Vargas-Díaz et al. | Stereochemistry of optically active nickel (II) and cobalt (II) coordination compounds derived from N-acetyl aminoalcohols | |
Wu | Synthesis and characterization of ruthenium maltolato, sulfoxide, and nitroimidazole complexes as potential anticancer agents | |
JPS6345291A (ja) | ジアミン白金錯体の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase |